Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models

Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver, affecting around 35% of the world population. Various circumstances contribute to the initiation and progression of NAFLD, and it encompasses a wide range of disorders, from simple steatosis to nonalcoholic...

Full description

Saved in:
Bibliographic Details
Published in:PPAR research 2022-06, Vol.2022, p.1-12
Main Authors: Mahmoudi, Ali, Moallem, Seyed Adel, Johnston, Thomas P., Sahebkar, Amirhossein
Format: Article
Language:English
Subjects:
Amino acids
Animal models
Animals
Antioxidants
Apolipoproteins
Cholesterol
Cirrhosis
Clinical trials
Diabetes
Diet
Drug approval
Dyslipidemia
Fatty acids
Fatty liver
Fenofibrate
Glucose
Inflammation
Insulin resistance
Investigations
Lipids
Lipogenesis
Lipoproteins
Liver
Liver cancer
Liver cirrhosis
Liver diseases
Medical research
Medicine, Experimental
Metabolic disorders
Obesity
Pharmaceutical industry
Review
Steatosis
Type 2 diabetes
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver, affecting around 35% of the world population. Various circumstances contribute to the initiation and progression of NAFLD, and it encompasses a wide range of disorders, from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Although several treatments have been proposed, there is no definitive cure for NAFLD. In recent decades, several medications related to other metabolic disorders have been evaluated in preclinical studies and in clinical trials due to the correlation of NAFLD with other metabolic diseases. Fenofibrate is a fibrate drug approved for dyslipidemia that could be used for modulation of hepatic fat accumulation, targeting peroxisome proliferator-activator receptors, and de novo lipogenesis. This drug offers potential therapeutic efficacy for NAFLD due to its capacity to decrease the accumulation of hepatic lipids, as well as its antioxidant, anti-inflammatory, and antifibrotic properties. To better elucidate the pathophysiological processes underlying NAFLD, as well as to test therapeutic agents/interventions, experimental animal models have been extensively used. In this article, we first reviewed experimental animal models that have been used to evaluate the protective effects of fenofibrate on NAFLD/NASH. Next, we investigated the impact of fenofibrate on the hepatic microcirculation in NAFLD and then summarized the beneficial effects of fenofibrate, as compared to other drugs, for the treatment of NAFLD. Lastly, we discuss possible adverse side effects of fenofibrate on the liver.
ISSN:1687-4757
1687-4765
DOI:10.1155/2022/5805398